account_balance
Investment manager · 13F filer · SEC CIK 1622627
Rosalind Advisors, Inc.
Reported value$266Mas of Jun 30, 2026
Positions29 3 new, 6 sold out
Top 10 weight74.9%DCTH alone is 16%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
DCTHDelcath Systems, Inc.
15.6%
FENCFennec Pharmaceuticals Inc
12.9%Added +10%
XERSXeris Biopharma Holdings Inc
8.7%Trimmed −10%
SVRASavara Inc
7.4%
VSTMVerastem Inc
5.7%Added +86%
XFORX4 Pharmaceuticals Inc
5.6%
EYPTEyepoint Pharmaceuticals Inc
5.3%Trimmed −5%
HELPCybin Inc
4.9%Added +28%
VORVor Biopharma Inc
4.5%Trimmed −7%
PCVXVaxcyte Inc
4.4%Trimmed −31%
MDWDMediwound Ltd
4.1%
CLDXCelldex Therapeutics Inc
2.8%Trimmed −39%
DCTHDelcath Systems, Inc.
15.6%
FENCFennec Pharmaceuticals Inc
12.9%Added +10%
XERS8.7%SVRA7.4%VSTM5.7%XFOR5.6%EYPT5.3%HELP4.9%VOR4.5%PCVX4.4%MDWD4.1%CLDX2.8%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
DCTH Delcath Systems, Inc. 15.6% HeldFENC Fennec Pharmaceuticals Inc 12.9% Added +10%XERS Xeris Biopharma Holdings Inc 8.7% Trimmed −10%SVRA Savara Inc 7.4% HeldVSTM Verastem Inc 5.7% Added +86%XFOR X4 Pharmaceuticals Inc 5.6% HeldEYPT Eyepoint Pharmaceuticals Inc 5.3% Trimmed −5%HELP Cybin Inc 4.9% Added +28%VOR Vor Biopharma Inc 4.5% Trimmed −7%PCVX Vaxcyte Inc 4.4% Trimmed −31%MDWD Mediwound Ltd 4.1% HeldCLDX Celldex Therapeutics Inc 2.8% Trimmed −39%
What changed